Loading company…
San Francisco biopharma developing immunotherapies for oncology and complex conditions; acquired by Ikena Oncology in 2023.
Founded in 2015 and based in San Francisco, US, Pionyr Immunotherapeutics, Inc. develops immunotherapies intended to address unmet medical needs, particularly in oncology. Co-founder Max Krummel has a history of founding pharmaceutical companies. Gilead Sciences acquired a 49.9 percent stake for USD 275.00 mn in June 2020, and Ikena Oncology, Inc. acquired the company in full in August 2023. Pionyr has completed six deals, with a total of USD 275.00 mn raised.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in